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In early 2013, the novel H7N9 influenza virus was identi-
fied as a human-infecting virus in China. The virus causes 
pneumonia, respiratory failure, acute respiratory distress 
syndrome, multi-organ failure and death [1]. As of 27 May 
2013, 130 known cases of H7N9 infection were confirmed 
for mainland China. Of these cases, 36 resulted in death, 
while 57 patients have recovered according to the Chinese 
National Health and Family Planning Commission. At the 
commencement of the H7N9 outbreak, health care providers 
worldwide, especially those in front-line clinical areas such 
as emergency rooms and outpatient clinics, began to prepare 
to cope with a potential flu pandemic. All cases of infection 
to date have been sporadic, without evidence of human-to-       
human transmission. Chinese provincial governments ter-
minated their emergency response to H7N9 on 30 May 
2013 after no new human infection was reported for 21 
consecutive days. However, the H7N9 bird flu is still of 
global concern from a public health standpoint, as the re-
sulting mortality of H7N9 infection [2] is very high. 
The H7N9 virus is a serotype of influenza virus A, also 
known as an avian influenza serotype or, more colloquially 
as a “bird flu” virus. Hemagglutinin (HA) and neuramini-
dase (NA) are two large glycoproteins on the outside of the 
viral particles which aid in classifying influenza A into 
subtypes based on antibody responses to HA and NA. HA is 
a lectin that mediates binding of the virus to target cells, and 
serves as an entry point for the viral genome into the target 
cell. NA is involved in the release of progeny virus from 
infected cells by cleaving sugars that bind to the mature 
viral particles. Different types of HA and NA help in dif-
ferentiating between serotypes such as H5N1 and H7N9. 
There are 16 HA and 9 NA subtypes that are known to exist; 
however, H1–H3 and N1–2 are commonly found in humans. 
Because of the high mutation rate of the virus, H5, N7, and 
N9 have also been observed in humans. 
What will be the next novel serotype to infect humans? 
This is hard to predict because of the high mutation rates 
and variations in influenza viruses. Because of these factors, 
it is also very difficult to prevent novel influenza sub-        
serotypes from spreading. Human beings are susceptible to 
influenza viruses, and there are no known effective methods 
to predict which strain of virus will be the next serotype to 
cause a pandemic. It is known that some serotypes of influ-
enza virus, such as H7N9, H5N1 and H1N1 are fatal. There 
is no single vaccine that covers all known and unknown 
strains. It usually takes about six months to produce and 
distribute a vaccine against a new strain of influenza. All of 
these contributing factors make humans particularly suscep-
tible to infection by novel influenza viruses. 
Although the H7N9 emergency response system was 
terminated at the end of May 2013, H7N9 could cause more 
problems in the future. Because of the high mutation rate of 
the virus, we should not only focus on researching varia-
tions of the virus to investigate what is the most likely 
emerging serotype, but also assess the pathogenicity of 
serotypes. As the current flu vaccine is reformulated each 
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season for a few, but not all influenza strains, it is impossi-
ble to offer protection against emerging pandemic strains 
that may happen to break out. Therefore, multivalent vac-
cines should be further explored as these will assist with 
protecting against multiple influenza strains. Developing 
and improving the monitoring network of influenza infec-
tions, and pneumonia with unknown causes, along with 
strengthening the current early warning system is a key 
strategy in preventing an influenza pandemic. 
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